PDCD1 and colorectal carcinoma: To investigate the impact of tumor metabolic features on immune responses, we analyzed a single cell RNA sequencing (scRNA-seq) dataset GSE205506 from 17 colorectal cancer (CRC) patients who underwent neoadjuvant PD-1 blockade therapy (toripalimab) (12).